Back to Search Start Over

Genome-wide Association Study Identifies HLA-DPB1 as a Significant Risk Factor for Severe Aplastic Anemia

Authors :
Colm O'hUigin
Stephanie J. Lee
Sonja I. Berndt
Aurelie Vogt
Qing Lan
Susan L. Slager
Shengchao Alfred Li
Stephen J. Chanock
Shahinaz M. Gadalla
Amanda Willis
Belynda Hicks
Stephen R. Spellman
Mary Carrington
Meredith Yeager
Nathaniel Rothman
Mathias Viard
Weiyin Zhou
Michael D. Haagenson
Youjin Wang
Charles C. Chung
Sharon A. Savage
James R. Cerhan
Nicolas Vince
Michael Dean
Laurie Burdett
Veron Ramsuran
Kelvin C. de Andrade
Medhat Askar
Tao Wang
Neal D. Freedman
Yawei Zhang
Lauren R. Teras
Division of Cancer Epidemiology and Genetics [Bethesda, MD, États-Unis]
National Cancer Institute [Bethesda] (NCI-NIH)
National Institutes of Health [Bethesda] (NIH)-National Institutes of Health [Bethesda] (NIH)
Frederick National Laboratory for Cancer Research (FNLCR)
National Institutes of Health [Bethesda] (NIH)
University of Wisconsin - Milwaukee
University of KwaZulu-Natal (UKZN)
Institut de transplantation urologie-néphrologie (ITUN)
Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)
Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE)
Université de Nantes (UN)-Université de Nantes (UN)
Department of Health Sciences Research [Mayo Clinic] (HSR)
Mayo Clinic
Yale School of Public Health (YSPH)
American Cancer Society [Atlanta, GA, USA]
Baylor University
Fred Hutchinson Cancer Research Center [Seattle] (FHCRC)
Massachusetts Institute of Technology (MIT)
This work was supported by the intramural research programof the Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI). The Center for International Blood and Marrow Transplant Research (CIBMTR) is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the NCI, the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID)
Grant/Cooperative Agreement 4U10HL069294 from the NHLBI and the NCI
contract HHSH250201200018C with the Health Resources and Services Administration (HRSA/ DHHS)
and two grants, N00014-17-1-2388 and N0014-17-1-2850, from the Office of Naval Research. The Mayo Clinic Case-Control Study of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (MAYO) study is funded through grants R01 CA92153 and P50 CA97274. TheNCI Surveillance, Epidemiology, and End Results Non-Hodgkin Lymphoma Case-Control Study (NCI-SEER) study is funded by the Intramural Research Programof theNCI,National Institutes of Health (NIH), and Public Health Service (N01-PC-65064, N01-PC-67008, N01-PC-67009, N01-PC-67010, and N02-PC- 71105). The Population-based Case-Control Study in Connecticut Women (YALE) is funded through the NCI (CA62006 and CA165923). This project has also been funded in part with federal funds from the Frederick National Laboratory for Cancer Research, under Contract No. HHSN261200800001E.
University of KwaZulu-Natal [Durban, Afrique du Sud] (UKZN)
Le Bihan, Sylvie
Source :
American Journal of Human Genetics, American Journal of Human Genetics, Elsevier (Cell Press), 2020, 106 (2), pp.264-271. ⟨10.1016/j.ajhg.2020.01.004⟩, Am J Hum Genet, American Journal of Human Genetics, 2020, 106 (2), pp.264-271. ⟨10.1016/j.ajhg.2020.01.004⟩
Publication Year :
2020
Publisher :
HAL CCSD, 2020.

Abstract

International audience; Severe aplastic anemia (SAA) is a rare disorder characterized by hypoplastic bone marrow and progressive pancytopenia. The etiology of acquired SAA is not understood but is likely related to abnormal immune responses and environmental exposures. We conducted a genome-wide association study of individuals with SAA genetically matched to healthy controls in discovery (359 cases, 1,396 controls) and validation sets (175 cases, 1,059 controls). Combined analyses identified linked SNPs in distinct blocks within the major histocompatibility complex on 6p21. The top SNP encodes p.Met76Val in the P4 binding pocket of the HLA class II gene HLA-DPB1 (rs1042151A>G, odds ratio [OR] 1.75, 95% confidence interval [CI] 1.50–2.03, p = 1.94 × 10−13) and was associated with HLA-DP cell surface expression in healthy individuals (p = 2.04 × 10−6). Phylogenetic analyses indicate that Val76 is not monophyletic and likely occurs in conjunction with different HLA-DP binding groove conformations. Imputation of HLA-DPB1 alleles revealed increased risk of SAA associated with Val76-encoding alleles DPB1∗03:01, (OR 1.66, p = 1.52 × 10−7), DPB1∗10:01 (OR 2.12, p = 0.0003), and DPB1∗01:01 (OR 1.60, p = 0.0008). A second SNP near HLA-B, rs28367832G>A, reached genome-wide significance (OR 1.49, 95% CI 1.22–1.78, p = 7.27 × 10−9) in combined analyses; the association remained significant after excluding cases with clonal copy-neutral loss-of-heterozygosity affecting class I HLA genes (8.6% of cases and 0% of controls). SNPs in the HLA class II gene HLA-DPB1 and possibly class I (HLA-B) are associated with SAA. The replacement of Met76 to Val76 in certain HLA-DPB1 alleles might influence risk of SAA through mechanisms involving DP peptide binding specificity, expression, and/or other factors affecting DP function.

Details

Language :
English
ISSN :
00029297 and 15376605
Database :
OpenAIRE
Journal :
American Journal of Human Genetics, American Journal of Human Genetics, Elsevier (Cell Press), 2020, 106 (2), pp.264-271. ⟨10.1016/j.ajhg.2020.01.004⟩, Am J Hum Genet, American Journal of Human Genetics, 2020, 106 (2), pp.264-271. ⟨10.1016/j.ajhg.2020.01.004⟩
Accession number :
edsair.doi.dedup.....1089560a6aad33f8fba746160e5ec92d
Full Text :
https://doi.org/10.1016/j.ajhg.2020.01.004⟩